The Timing and Probability of Treatment Switch under Cost Uncertainty: An Appli...

• Autor(es): Sampayo, F.
• Data: 2014
• Identificador Persistente: http://hdl.handle.net/10071/7387
• Origem: Repositório do ISCTE-IUL
• Assunto(s): Cost uncertainty; Decision analysis; Economic evaluation; Health economics; Switch treatments
• Tipo de Documento: Artigo
• Idioma: Inglês

Descrição

WOS:000333346600008 (Nº de Acesso Web of Science) Background: Cost fluctuations render the outcome of any treatment switch uncertain, so that decision makers might have to wait for more information before optimally switching treatments, especially when the incremental cost per quality-adjusted life year (QALY) gained cannot be fully recovered later on Objective: To analyze the timing of treatment switch under cost uncertainty. Methods: A dynamic stochastic model for the optimal timing of a treatment switch is developed and applied to a problem in medical decision taking, i.e. to patients with unresectable gastrointestinal stromal tumour (GIST). Results: the theoretical model suggests that cost uncertainty reduces expected net benefit. In addition, cost volatility discourages switching treatments. the stochastic model also illustrates that as technologies become less cost competitive, the cost uncertainty becomes more dominant. With limited substitutability, higher quality of technologies will increase the demand for those technologies disregarding the cost uncertainty. The results of the empirical application suggest that the first-line treatment may be the better choice when considering lifetime welfare. Conclusions: Under uncertainty and irreversibility, low-risk patients must begin the second-line treatment as soon as possible, which is precisely when the second-line treatment is least valuable. As the costs of reversing current treatment impacts fall, it becomes more feasible to provide the option-preserving treatment to these low-risk individuals later on.